Physician profile
Sharon E Long
NPI 1568440725
$5,443.22
in general payments reported to CMS, 2019-2025
27 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $871 · 2023: $1,095 · 2024: $1,603 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,032.52 | 2021-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $578.15 | 2021-2024 | Ajovy, Austedo Xr |
| Novo Nordisk INC | $422.05 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $320.72 | 2022-2025 | Wainua |
| Otsuka America Pharmaceutical, INC. | $249.48 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $237.63 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $214.53 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $204.34 | 2023-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $189.51 | 2023-2024 | |
| Averitas Pharma INC. | $144.96 | 2025 | Qutenza |
| Inspire Medical Systems, INC. | $141.92 | 2023 | Inspire |
| Silk Road Medical, INC. | $141.60 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abiomed | $139.15 | 2024 | Impella |
| Medtronic, INC. | $135.21 | 2023 | Interstim |
| Agios Pharmaceuticals, INC. | $124.99 | 2025 | Pyrukynd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $123.75 | 2024 | Hyqvia |
| Lilly USA, LLC | $121.86 | 2024 | Omvoh |
| Lundbeck LLC | $115.00 | 2023 | Vyepti |
| Viiv Healthcare Company | $107.10 | 2024 | Dovato |
| Rhythm Pharmaceuticals, INC. | $103.19 | 2021 | |
| Axsome Therapeutics, INC. | $102.15 | 2025 | Auvelity |
| Corcept Therapeutics | $100.00 | 2021 | |
| Eisai INC. | $93.70 | 2025 | |
| Amarin Pharma, INC. | $90.92 | 2024 | |
| Acadia Pharmaceuticals INC | $84.74 | 2024 | Nuplazid |
| Sk Life Science, INC. | $79.62 | 2022 | |
| Coloplast Corp | $44.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.